Cargando…

Immunosenescence is a therapeutic target for frailty in older adults: a narrative review

BACKGROUND AND OBJECTIVE: Aging refers to a progressive decrease in functional performance, leading to increased mortality risk. At present, life expectancy is increasing worldwide and is expected to exceed 80 years by 2040. However, this increase in life expectancy also indicates a rise in the inci...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Huanan, Huang, Wei, Liu, Chuanfeng, Tang, Shiyu, Zhang, Jing, Chen, Chongli, Tian, Yuan, Zhong, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652526/
https://www.ncbi.nlm.nih.gov/pubmed/36388790
http://dx.doi.org/10.21037/atm-22-4405
_version_ 1784828488604188672
author Jia, Huanan
Huang, Wei
Liu, Chuanfeng
Tang, Shiyu
Zhang, Jing
Chen, Chongli
Tian, Yuan
Zhong, Wen
author_facet Jia, Huanan
Huang, Wei
Liu, Chuanfeng
Tang, Shiyu
Zhang, Jing
Chen, Chongli
Tian, Yuan
Zhong, Wen
author_sort Jia, Huanan
collection PubMed
description BACKGROUND AND OBJECTIVE: Aging refers to a progressive decrease in functional performance, leading to increased mortality risk. At present, life expectancy is increasing worldwide and is expected to exceed 80 years by 2040. However, this increase in life expectancy also indicates a rise in the incidence and prevalence of diseases, such as cardiovascular, neurological, musculoskeletal, and oncological diseases, which are associated with aging. The exact underlying mechanisms of aging remain unknown, and whether it is a programmed process or the consequence of an accumulation of stress events remains unclear. Thus, more scientific research is needed to improve the management of complex and frail patients. METHODS: Several databases were searched with the following key words: immunosenescence, inflamm-aging, frailty, sarcopenia and skeletal muscle, etc. KEY CONTENT AND FINDINGS: Skeletal muscle is the core phenotype of frailty and sarcopenia. Immune aging and skeletal muscle decline interplay with each other and form a vicious circle. Maintaining muscle health is beneficial for immune function and delays the onset of frailty. Particularly, in the context of the ongoing corona virus disease (COVID)-19 pandemic, studies have shown that the elderly are more prone to the consequences of the SARS-CoV-2 virus. It has been reported that the rates of hospitalization in the 65–74, 75–84, and ≥85 years old group were 5×, 8×, and 10× greater than the 18–29 years old group, with corresponding COVID-19-related deaths being 60×, 140×, and 330× that of the younger reference group, respectively. Considering the above, this review aims to discuss the relationship between immunosenescence, skeletal muscle, and frailty, and to explore immunosenescence as a potential therapeutic target to prevent frailty and extend healthspan, with some emphasis on the effects of the COVID-19 pandemic on the elderly. CONCLUSIONS: Immunosenescence is a promising potential therapeutic target for frailty and is worthy of further investigation.
format Online
Article
Text
id pubmed-9652526
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-96525262022-11-15 Immunosenescence is a therapeutic target for frailty in older adults: a narrative review Jia, Huanan Huang, Wei Liu, Chuanfeng Tang, Shiyu Zhang, Jing Chen, Chongli Tian, Yuan Zhong, Wen Ann Transl Med Review Article BACKGROUND AND OBJECTIVE: Aging refers to a progressive decrease in functional performance, leading to increased mortality risk. At present, life expectancy is increasing worldwide and is expected to exceed 80 years by 2040. However, this increase in life expectancy also indicates a rise in the incidence and prevalence of diseases, such as cardiovascular, neurological, musculoskeletal, and oncological diseases, which are associated with aging. The exact underlying mechanisms of aging remain unknown, and whether it is a programmed process or the consequence of an accumulation of stress events remains unclear. Thus, more scientific research is needed to improve the management of complex and frail patients. METHODS: Several databases were searched with the following key words: immunosenescence, inflamm-aging, frailty, sarcopenia and skeletal muscle, etc. KEY CONTENT AND FINDINGS: Skeletal muscle is the core phenotype of frailty and sarcopenia. Immune aging and skeletal muscle decline interplay with each other and form a vicious circle. Maintaining muscle health is beneficial for immune function and delays the onset of frailty. Particularly, in the context of the ongoing corona virus disease (COVID)-19 pandemic, studies have shown that the elderly are more prone to the consequences of the SARS-CoV-2 virus. It has been reported that the rates of hospitalization in the 65–74, 75–84, and ≥85 years old group were 5×, 8×, and 10× greater than the 18–29 years old group, with corresponding COVID-19-related deaths being 60×, 140×, and 330× that of the younger reference group, respectively. Considering the above, this review aims to discuss the relationship between immunosenescence, skeletal muscle, and frailty, and to explore immunosenescence as a potential therapeutic target to prevent frailty and extend healthspan, with some emphasis on the effects of the COVID-19 pandemic on the elderly. CONCLUSIONS: Immunosenescence is a promising potential therapeutic target for frailty and is worthy of further investigation. AME Publishing Company 2022-10 /pmc/articles/PMC9652526/ /pubmed/36388790 http://dx.doi.org/10.21037/atm-22-4405 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Jia, Huanan
Huang, Wei
Liu, Chuanfeng
Tang, Shiyu
Zhang, Jing
Chen, Chongli
Tian, Yuan
Zhong, Wen
Immunosenescence is a therapeutic target for frailty in older adults: a narrative review
title Immunosenescence is a therapeutic target for frailty in older adults: a narrative review
title_full Immunosenescence is a therapeutic target for frailty in older adults: a narrative review
title_fullStr Immunosenescence is a therapeutic target for frailty in older adults: a narrative review
title_full_unstemmed Immunosenescence is a therapeutic target for frailty in older adults: a narrative review
title_short Immunosenescence is a therapeutic target for frailty in older adults: a narrative review
title_sort immunosenescence is a therapeutic target for frailty in older adults: a narrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652526/
https://www.ncbi.nlm.nih.gov/pubmed/36388790
http://dx.doi.org/10.21037/atm-22-4405
work_keys_str_mv AT jiahuanan immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview
AT huangwei immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview
AT liuchuanfeng immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview
AT tangshiyu immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview
AT zhangjing immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview
AT chenchongli immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview
AT tianyuan immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview
AT zhongwen immunosenescenceisatherapeutictargetforfrailtyinolderadultsanarrativereview